| http://www.w3.org/ns/prov#value | - Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the ultimate results of clinical development of the Company's proposed estradiol VagiCap drug; the Company's belief that the PK data suggests that TX 12-004-HR may provide therapeutic advantages over Vagifem; the Company's belief that the side effects associated with
|
